New AI-generated COVID drug enters Phase I clinical trials: ‘Effective against all variants’
Once approved, the oral medication would provide another antiviral option: ‘A promising alternative’
Artificial intelligence is increasingly moving into the health care arena and helping to streamline medical processes — including the creation of new drugs.
Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials.
This oral drug is a treatment, not a vaccine. If approved, it would become an alternative to the current COVID antivirals including Paxlovid and Lagevrio, noted Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.
"Generative AI is transforming every area of human development," said Zhavoronkov in a press release announcing the new discovery.
"We’re extremely happy to announce that our second small molecule therapeutic — generated using generative AI — is now entering human clinical trials."
